https://www.selleckchem.com/pr....oducts/2-2-2-tribrom
A total of 40.9% of COVID+ SOT experienced a major adverse renal or cardiac event, 16.3% experienced a major adverse cardiac event, 35.3% experienced AKI, and 1.5% experienced graft loss. In the largest US cohort of COVID+ SOT recipients to date, we identified patient factors associated with the diagnosis of COVID-19 and outcomes following infection, including a high incidence of major adverse renal or cardiac event and AKI. In the largest US cohort of COVID+ SOT recipients to date, we identified patient factors associated
Like
Comment
Share
